Akeso

This phase 3 trial is testing whether adding the immunotherapy drug AK104 (cadonilimab) before and after surgery can improve outcomes for people with a specific type of colon cancer (MSI-H/dMMR). About 386 participants will be randomly assigned to receive either AK104 plus standa…

This phase 3 trial is testing whether adding the experimental drug ivonescimab to standard chemotherapy (docetaxel) helps people with advanced non-small cell lung cancer live longer. The study includes 536 adults whose cancer worsened after prior immunotherapy. Participants are r…

This study tests whether two experimental drugs, AK119 and AK112, can safely shrink or control advanced solid tumors that have stopped responding to standard treatments. About 87 adults with various solid tumors will receive the drug combination. The main goals are to check safet…

This study tests whether adding the drug AK112 to standard chemotherapy (nab-paclitaxel) helps people with advanced triple-negative breast cancer live longer without their cancer growing. About 416 adults who have not had prior treatment for advanced disease will be randomly assi…

This phase 2 trial is testing a combination of two immunotherapy drugs (AK104 and AK112) plus a targeted pill (TT-00420) in 100 people with advanced hepatocellular carcinoma that cannot be treated with local therapies. The main goal is to see how many patients' tumors shrink. Par…

This study tests a new drug called AK112, alone or with other treatments, for people with advanced liver cancer that hasn't responded to standard care. The first part checks safety and the right dose, while the second part compares the new combinations to existing therapies. Abou…

This Phase 3 trial is testing whether AK112 (Ivonescimab), a bispecific antibody that targets both PD-1 and VEGF, can help prevent cancer progression in people with limited-stage small-cell lung cancer who have completed chemoradiation. About 560 participants will receive either …

This phase 3 study compares a new drug, AK112, combined with chemotherapy against the standard treatment (bevacizumab plus chemo) for people with metastatic colorectal cancer that has not been treated before. The goal is to see if the new combination helps patients live longer wi…

This large Phase 3 trial tests whether adding two immune-boosting drugs (ivonescimab and AK117) to standard chemotherapy helps people with metastatic pancreatic cancer live longer. About 999 participants will be randomly assigned to get the new drugs or a placebo, all with chemo.…

This study tests whether combining two drugs, AK130 and AK112, can help control advanced pancreatic cancer. About 160 adults whose cancer has worsened after up to two prior treatments will receive the combination or AK112 alone. The goal is to see if the treatment shrinks tumors …

This study tests two experimental drugs, AK130 and AK112, in people with advanced biliary tract cancer (a type of bile duct cancer). The first part finds a safe dose; the second part checks if the combination shrinks tumors. About 135 participants will take part.

This study tests whether adding the drug cadonilimab to standard chemotherapy (SOX) before and after surgery helps people with stomach or gastroesophageal junction cancer that can be removed. About 760 participants will receive either cadonilimab plus chemo or a placebo plus chem…

This study tests whether adding the drug cadonilimab to standard chemotherapy before and after surgery helps people with a certain type of esophageal cancer. About 90 adults with resectable, locally advanced cancer will take part. The goal is to see if the combination leads to mo…

This early-stage study tests a new drug called AK138D1 in up to 200 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. Researchers will also look for early signs that the drug may…

This study tests whether adding extra immunotherapy drugs to standard chemotherapy can better control extensive-stage small cell lung cancer. About 180 adults who have not had prior treatment will be randomly assigned to one of three groups, all receiving the immunotherapy ivones…

This study tests two experimental drugs, AK109 and AK104, with or without chemotherapy, for people with advanced stomach or gastroesophageal junction cancer that has not responded to first-line treatment. The goal is to see if the combination can shrink tumors or slow disease pro…

This early-phase study tests a new drug called AK146D1 in 200 adults with advanced solid tumors that have worsened after standard treatments. The drug is designed to attach to two proteins (Trop2 and Nectin4) on cancer cells and deliver a toxic payload. The main goals are to chec…

This study is not testing a new treatment. Instead, it follows up with 610 people who previously received cadonilimab for advanced gastric cancer in earlier trials. Researchers will collect long-term survival data to see if the drug's benefits last. No additional medication is gi…